Hematology Frontier Archives - Page 86 of 87

Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

By Mourabit Halima 2024.01.05

Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of "The Voice of China" on the international stage. ASH is one of the largest and most comprehensive international academic conferences in the field of hematology globally, attracting numerous experts and scholars from around the world each year, including a significant representation from China. On the second day of the conference, we had the privilege of interviewing Professor Ma Jun, a leading figure in the field of hematology in China and the Director of the Harbin Institute of Hematology and Oncology. He shared his insights and highlights of this year's conference. Below is Professor Ma Jun's perspective:

2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

By Mourabit Halima 2024.01.04

The 65th Annual Meeting of the American Society of Hematology (ASH) recently concluded, with significant contributions in the field of Chronic Myeloid Leukemia (CML) treatment. Professor Jiang Qian and her team from Peking University People's Hospital presented multiple studies, with abstracts 867 and 869 selected for oral presentations. These reports highlighted the potential of TGRX-678 and Olverembatinib in CML treatment and overcoming drug resistance. "Hematology Frontier" had the privilege of interviewing Professor Jiang Qian on these topics.

Professor Xiaojun Huang Awarded International Collaboration Award by IACH

By Peter W. PENG 2024.01.04

Renowned hematologist Professor Xiaojun Huang has been honored with the International Collaboration Award by the International Academy for Clinical Hematology (IACH). Prof. Huang, a pioneer in the successful implementation of haploidentical transplantation, has significantly contributed to the field of clinical hematology and played a crucial role in promoting global collaboration. The award ceremony took place on October 5, 2023, during the IACH annual meeting held in Paris. Professor Mohamad Mohty, the current president of IACH, praised Xiaojun Huang 's outstanding achievements and key contributions to international collaboration in his invitation and award speech.

Year-End Review | Professor Jianxiang Wang: Targeted New Drugs Lead the Wave of Advances in AML Treatment, Immunotherapy Also on the Rise!

By Lisa Cui 2024.01.03

Acute Myeloid Leukemia (AML) is a malignant clonal disease originating from hematopoietic stem cells. Affected myeloid cells (leukemic cells) undergo uncontrolled proliferation, differentiation disorders, and blocked apoptosis, accumulating in the bone marrow and other hematopoietic tissues. This inhibits normal hematopoietic function and infiltrates organs such as lymph nodes, liver, and spleen, leading to clinical features including anemia, infections, bleeding, and leukemic cell infiltration. As the most common hematologic malignancy, research in the field of AML, both basic and clinical, has never ceased, yielding continuous breakthroughs. So, what significant advancements has the AML field witnessed in the past year? "Oncology Frontier" has invited Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences, to meticulously review various developments in the AML domain. The summary is compiled below.

How to choose the maintenance treatment plan after HSCT for R/R malignanthematological patients?

By Peter W. PENG 2023.10.13

Relapse/refractory (R/R) has always been a difficult point in the clinical treatment of malignant hematological tumors. Hematopoietic stem cell transplantation (HSCT) is an important treatment for these patients to achieve long-term survival. Subsequent maintenance treatment is essential to consolidate the effects of HSCT and prevent disease recurrence. Therefore, researchers have been focusing on optimizing the specific maintenance treatment plan for a long time.

Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

By Peter W. PENG 2023.10.12

The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology and discussing the latest advances in hematology. In the treatment of acute lymphoblastic leukemia (ALL), there was significant progress made at this EHA meeting, mainly focused on immunotherapy. To further grasp the content in this area, Oncology Frontier interviewed Professor Ma Jun from the Harbin Institute of Hematology & Oncology and discussed this topic in detail.

Dr. HuiqiangHuang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.

By Peter W. PENG 2023.10.12

Extranodal NK/T-cell lymphoma (ENKTCL) of nasal type is a rare subtype, commonly found in the Asian population and associated with the Epstein-Barr Virus (EBV). At present, the prognosis for patients remains poor, especially for relapsed/refractory (R/R) cases. From June 8 to 11, 2023, the 28th European Hematology Association (EHA) annual meeting was held in Frankfurt, Germany. A selected oral report (Abstract No.: S226) from the conference showed that the use of PD-1 inhibitors alone or in combination significantly improved the treatment of R/R ENKTCL patients. This study further confirmed that immune checkpoint inhibitors have become an important treatment option for R/R ENKTCL patients. Oncology Frontier invited Dr. Huiqiang Huang from Sun Yat-sen University Cancer Center to share the research findings and insights at the conference.

Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia

By Peter W. PENG 2023.10.12

T-cell lymphoblastic lymphoma (T-LBL) is a highly malignant and rare lymphoma with aggressive behavior. It primarily affects adolescents, often presenting with mediastinal lymph node enlargement and commonly accompanied by pericardial and pleural effusions. In some cases, the disease can involve the central nervous system (CNS) with neurological manifestations. About 20% of patients progress to acute T-cell lymphoblastic leukemia (T-ALL) in advanced stages, which has a rapid progression and poor prognosis.

Dr. QianJiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

By Peter W. PENG 2023.10.12

From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.

$Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases at 2023 EHA$

Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases at 2023 EHA

By Peter W. PENG 2023.10.12

The 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany, from June 8 to 11, 2023. Dr Xiaofan Zhu and his team from the Children's Hematology Center at the Chinese Academy of Medical Sciences and Peking Union Medical College presented four abstracts at this EHA congress. These abstracts covered various aspects of research, including the prognostic factors for relapsed childhood acute lymphoblastic leukemia (ALL) treated with the CCLG-ALL2008 protocol in China, the use of Blinatumomab for 14 days in combination with chemotherapy to achieve minimal residual disease (MRD) conversion in pediatric B-ALL patients, the integration of transcriptomic features to improve prognosis prediction in pediatric acute myeloid leukemia (AML) with KMT2A rearrangements, and the effective treatment of pediatric non-sickle cell anemia (NSAA) with Hydroxyurea in combination with CSA. To gain a deeper understanding of these studies, Dr. Zhu has provided interpretations of the research findings, which are summarized below.